Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052968 | 1.00 | DPP4 (0.39) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL20002184 | 1.00 | DPP4 (0.39) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL21135782 | 1.00 | DPP4 (0.39) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL19995995 | 1.00 | DPP4 (0.39) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL20002702 | 0.84 | DPP4 (0.41) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL20002704 | 0.84 | DPP4 (0.41) | DPP4ARDPP8FAPDPP9 | |
| SCHEMBL1830059 | 0.82 | HTRA1 (0.49) | DPP4ARHTRA1TACR1NR1H2 | |
| SCHEMBL1830060 | 0.82 | HTRA1 (0.49) | DPP4ARHTRA1TACR1NR1H2 | |
| SCHEMBL23454767 | 0.82 | CYP1A2 (0.38) | DPP4HTRA1TACR1NR1H2NR1H3 | |
| SCHEMBL21136402 | 0.82 | CYP1A2 (0.38) | DPP4HTRA1TACR1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL PORTELA & CA SA (PT) | 2023-05-04 | — | — | US | disclosed |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2022-09-06 | — | — | US | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056855-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | DPP4 685/4885AR 2170/4885DPP8 823/4885 |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | DBH, MAOB, COMT | DPP4 972/4885AR 1885/4885DPP8 1635/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | DPP4 820/4885AR 2292/4885DPP8 919/4885 |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | DPP4 1072/4885AR 2049/4885DPP8 1771/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | DPP4 680/4885AR 2188/4885DPP8 801/4885 |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, SLC6A3 | DPP4 1161/4885AR 1743/4885DPP8 1834/4885 |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, COMT | DPP4 877/4885AR 1570/4885DPP8 1449/4885 |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | DPP4 972/4885AR 1885/4885DPP8 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.